In this randomized, single-blind, casecontrolled, prospective study, the incidence and outcome of ceftriaxoneassociated biliary pseudolithiasis in Chinese children was evaluated via ultrasonography. A total of 108 children diagnosed with hepatobiliary infection or pneumonia were randomized to receive ceftriaxone or ceftazidime. Serial gallbladder sonograms were obtained on days 1, 5 -7 and 10 -14 of therapy. Gallstones were detected in 43.10% of patients in the ceftriaxone-treated group and in 2.00% of the ceftazidime-treated group. The incidence of pseudolithiasis was significantly higher in the ceftriaxone-treated than the ceftazidimetreated group. Biliary precipitation abnormalities appeared after 2 -7 days of treatment. After gallstones were found, the drug was stopped and symptoms resolved within 1 -2 days. This study suggests that the risk of ceftriaxoneassociated biliary pseudolithiasis should be considered when treating Chinese children.
Introduction
Ceftriaxone -a semi-synthetic, parenteral, third-generation, β-lactamase-resistant cephalosporin -is often used to treat childhood infections because of its wide spectrum of antimicrobial activity, long plasma half-life and once-daily administration. 1, 2 Approximately 33 -67% of the drug is excreted unchanged into the urine, 3 with the remainder eliminated via the biliary system. 4 Ceftriaxone is widely used in the treatment of liver or biliary tract infection. It can bind with calcium ions, producing a precipitate that forms biliary sludge, also known as biliary pseudolithiasis. 5 In addition, ceftriaxoneinduced nephrolithiasis has been reported. 6 -8 Several reports have documented reversible ceftriaxone-associated biliary sludge and pseudolithiasis during ceftriaxone therapy in adults and children; 2, 9, 10 this may be readily detected by ultrasonography. Biliary pseudolithiasis has been reported in up to 46% of children treated with ceftriaxone, 11 *D Meng, Y Cao, J Fu and R Chen contributed equally to this work. D Meng, Y Cao, J Fu et al.
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although only one study has described gallbladder sludge and gallstones during ceftriaxone treatment in Chinese children. 12 Because of the absence of large casecontrolled studies, this prospective, randomized, single-blind, case-control study was designed to use sonography to examine biliary precipitation abnormalities and pseudolithiasis during ceftriaxone therapy in Chinese children.
Patients and methods

PATIENTS
Children between the ages of 0.5 and 16 years, who were admitted for treatment of biliary tract infection or pneumonia, were recruited from the Children's Hospital of Chongqing Medical University, Chongqing, China, between January 2005 and June 2007. Those who had taken ceftriaxone or ceftazidime prior to hospitalization were excluded from participation. Patients with renal disease, hepatobiliary disease or any other chronic disease, those taking nephrotoxic medication, those with a history of hypersensitivity to ceftriaxone or ceftazidime, and those who refused ultrasonic examination were also excluded.
The study was approved by the Human Research Ethics Committee of the Children's Hospital of Chongqing Medical University. Patients' parents or caregivers were informed in detail about the study and written informed consent was obtained from all of them.
STUDY DESIGN
At study entry, patients were randomly assigned to one of two groups according to a computer-generated randomization schedule: ceftriaxone sodium treatment or ceftazidime treatment. A baseline ultrasonographic examination of the gallbladder was performed at treatment initiation.
Ceftriaxone sodium was administered at a dosage of 30 -80 mg/kg (based on the patient's body weight) intravenously once daily for 1 -3 weeks; ceftazidime was administered at a dosage of 50 -100 mg/kg intravenously once daily for 1 -3 weeks. No other antimicrobial agents were used concurrently.
DIAGNOSIS
A diagnosis of biliary tract infection was determined by the following symptoms: acute abdominal pain; disgorging; right upper quadrant tenderness; positive Murphy's sign; and ultrasonographic visualization of bile vessel wall echo enhancement; crud; gallbladder capsule wall thickening; and/or resonance coarse or double contour sign. Pneumonia was diagnosed by the following symptoms: fever; cough; pulmonary moist rales; and scattered shadow patches in the lung(s), visualized with X-ray. Cholecystolithiasis was defined as an ultrasound intraluminal echogenic structure casting a moveable distal acoustic shadow. Symptomatic and supportive treatments were provided according to the patient's primary disease.
ULTRASONOGRAPHY
Serial ultrasound evaluations of the gallbladder were performed on days 3 and 7 of ceftriaxone sodium/ceftazidime treatment and during the first and second months after the end of treatment. Patients with biliary sludge or pseudolithiasis underwent additional sonographic evaluation every 3 days until the abnormalities resolved. Urinalysis was performed in all patients, and ultrasonograpic examination of the urinary tract was performed in those with haematuria (i.e. the presence of red blood cells in the urine). Therapeutic measures for gallstone elimination were not applied to D Meng, Y Cao, J Fu et al.
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patients. Ultrasound images were interpreted blindly by two independent investigators.
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS ® statistical package, version 9.0 (SPSS, Chicago, IL, USA) for Windows ® . Differences between groups were assessed using the χ 2test, independent samples t-test or Fisher's exact test. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 67 biliary tract infection patients and 49 pneumonia patients received ceftriaxone or ceftazidime during the study period. Two patients with biliary tract infection were excluded because a biliary stone was detected in the gallbladder on the first day of treatment. Four patients with biliary tract infection and two patients with pneumonia were excluded because they were unwilling to undergo repeat ultrasonic examinations. Thus, 32 patients with biliary tract infection who received ceftriaxone and 29 who received ceftazidime, and 26 pneumonia patients who received ceftriaxone and 21 who received ceftazidime, were included in the final analysis. Of the 108 patients included in the analysis, 52 were girls and 56 were boys (age range 9 months -11 years; mean age 33.64 months; median age 29.41 months). Characteristics of the patients are shown in Table 1 .
Biliary precipitation abnormalities were detected via ultrasonography in 24.07% of all patients (26/108). In the ceftriaxonetreated groups, gallstones were detected in 43.10% of patients (25/58), compared with only 2.00% of patients (1/50) in the ceftazidime-treated groups (χ 2 = 24.82, P < 0.005). Table 2 shows the incidence of gallstones in each of the four study groups. The incidence of gallstone formation was statistically significantly higher in the ceftriaxone-treated patients with biliary tract infection than in any of the other three groups (P < 0.05) Biliary precipitation abnormalities appeared after 2 -7 days of treatment, with two patients having abnormalities on day 2, eight new patients on day 3, and 16 new patients on day 7. All of the patients with biliary precipitation abnormalities became symptomatic between 1 and 7 days after starting treatment, experiencing between one and five episodes of nausea and vomiting. Of the 26 patients affected, 16 (61.5%) experienced upper abdominal pain. As soon as gallstones were detected, Follow-up examinations showed the resolution of abnormal sonographic results within 7 -14 days in all except one patient, whose biliary precipitation abnormalities resolved completely on day 54 after the end of treatment. This patient had intermittent abdominal pain and aggravated vomiting during ceftriaxone treatment, which ceased on day 1 after discontinuation of therapy. The gallstone continued to enlarge for a week after ceftriaxone withdrawal, but began to resolve during the third week, disappearing on day 54. Of the other patients with biliary precipitation abnormalities, eight had resolved completely within 7 days after the end of treatment, and 17 resolved completely within 14 days. Routine urinalysis found no abnormalities in all 26 patients with gallstones.
Of the 26 patients with biliary precipitation abnormalities, eight had biliary sludge without muddy stone (detected in two patients on day 2 of treatment and in six patients on day 3; six of them had developed into muddy biliary stone by day 7) and 18 had muddy biliary stone (detected on day 3 of treatment in two patients and on day 17 in the remaining 16 patients). Typical ultrasonographic images before and after ceftriaxone-treatment are shown in Fig. 1 .
Post-study follow-up at different times (7 -54 days [mean ± SD 15.2 ± 26.5 days]) for 22 of the patients with biliary precipitation abnormalities revealed no abdominal pain, vomiting or other biliary symptoms during the follow-up period. Four patients were lost to follow-up.
Discussion
Paediatric gallbladder calculi are relatively uncommon; however, detection rates are increasing due to the increasing number of children undergoing abdominal ultrasound examinations. 13, 14 Children may harbour cholesterol gallstones, black-or brownpigmented stones, or mixed-type gallstones. 15 Conservative management and yearly follow-up ultrasonography is suggested for asymptomatic patients with no biochemical or radiological signs of common bile duct obstruction. 13 In contrast, surgical intervention is recommended for symptomatic patients and those with calcified stones that are unlikely to resolve 16, 17 Spontaneous resolution or elimination of gallbladder sludge or gallstones has been documented in neonates and young infants. 18 A number of risk factors are known to predispose children to cholelithiasis, 19 the most common being obesity, biliary dyskinesia, dehydration, intercurrent infection, haemolytic disorders and gallbladder hypomotility in childhood and adolescence. Gallstones may also be due to the use of medications, for example clofibrate. 20 Biliary sludge, or pseudolithiasis, is a known side-effect of ceftriaxone treatment. Ceftriaxone causes reversible pseudolithiasis through several mechanisms 21 and it detaches bilirubin from albumin, thereby increasing the blood concentration of unconjugated bilirubin. 22 Ceftriaxone concentration in the gallbladder can exceed serum concentrations 20-to 150-fold. 5 Normally, the liver eliminates a considerable proportion of ceftriaxone in the form of a soluble salt but, at high concentrations, ceftriaxone binds with calcium ions to form insoluble complexes that precipitate out in the biliary system. 23 The chemical composition of the sludge reveals a small amount of cholesterol and bilirubin and an abundant amount of ceftriaxone calcium salt. 26 It appears that stones can form in a similar way in the renal collecting system. 25 Reports on the formation of gallbladder sludge detected by ultrasound began with the introduction of ceftriaxone for clinical use, with Schaad et al. 26 demonstrating ceftriaxone-related sludge and pseudolithiasis in 1986. Herek et al. 9 showed an incidence of pseudolithiasis of 33%, while Schaad et al. 27 found reversible ceftriaxoneassociated biliary pseudolithiasis in approximately 43% of severely ill children treated with high doses of this drug. The incidence of sludge and pseudolithiasis formation in ceftriaxone-treated children in the present study was similar to other reports (43.10%). In contrast, there was only one (2.00%) case of biliary pseudolithiasis in the ceftazidime-treated group. This is the first study to compare the incidence of ceftriaxone-induced pseudolithiasis in pneumonia and biliary tract infection patients. The incidence of ceftriaxoneinduced pseudolithiasis was significantly higher in biliary tract infection patients than in pneumonia patients. The incidence of concomitant abdominal pain (61.5%) was higher than in other reports. 28 In accordance with previous reports, 2 all cases in the present study resolved after cessation of ceftriaxone therapy. Renal pseudolithiasis was not detected in any subject.
There may be several reasons for the high incidence of ceftriaxone-induced pseudolithiasis in children. First, compared with adults, the paediatric biliary system is long and thin, leading to inefficiency in the excretion of biliary sludge. Secondly, the level of cholecystokinin hormone is relatively low in children; cholecystokinin influences the size and the contraction ability of the gallbladder. 29 Thirdly, illness may cause loss of fluid, thus making it easier for sludge and pseudolithiasis to form. Lastly, the incidence of pseudolithiasis and biliary sludge was statistically significantly higher in patients with infection of the biliary tract, in the present study.
Analysis of the literature and the present study suggest that the use of ceftriaxone for treatment of biliary tract infection in children should be avoided. Ultrasonography should be used to detect cholelithiasis when symptoms such as nausea, vomiting and abdominal pain appear and, if pseudolithiasis is found, ceftriaxone should be ceased. Since all cases resolved after cessation of ceftriaxone therapy, surgery should be avoidable.
In conclusion, the present study suggests that the potential risk of ceftriaxoneassociated biliary pseudolithiasis in Chinese children must be considered when administering this drug.
